I can be staunch on IP protection in a lot of cases—but in the case of Martin Shkreli of Turing Pharmaceuticals AG hiking the price of an Aids drug from $13·50 to $750 per pill, not so much (for obvious reasons). If you’re in pharmaceuticals, then there has to be some element of wanting to benefit enough of humankind so that they can be, well, alive to better society—or, if you want to be monetarist about it, so they can consume more products and services. Whichever side of politics you’re on, productive people are a good thing for everyone except the arms’ industry. Yet the pharmaceutical industry is the one that’s trying to patent natural ingredients and phenomena—and that’s a step too far. It was something we were taught at law school that could not happen—how can a corporation own nature?—so for the industry to challenge both that jurisprudence smacks of greed. If you didn’t originate it, you shouldn’t be able to own it. Even if it could be protected, nature has been around long enough for that protection to have lapsed. Patenting genes? Please.
   Sure, everyone has the right to make a buck from intellectual endeavours, but their track record needs to be a lot cleaner. Why was there so much opposition to TPPA et al? Because there had been far too many cases of corporations taking the piss when it came to basic rights and established laws, and governments haven’t upped their game sufficiently. I love the idea of global trade, the notion “we’re all in this together”, but not at the expense of the welfare of fellow human beings. Simply, I give a shit. Hiking the price of something that costs $13·50 to $750 is laziness at the very least—let’s profit without lifting a finger—and being a douchebag at the worst. And I don’t believe we should reward either of these things.
   I have a friend who is against vaccinations—not a position I agree with—but his rationale boils down to his mistrust of Big Pharma. And why should he trust them, with these among their worst cases? (As far as I know, he doesn’t oppose other forms of IP protection.) Somewhere, there’s something that kicks off various positions, and corporate misbehaviour must fuel plenty.
   Meanwhile, here’s Martin Shkreli’s point of view, where he doesn’t see his actions as wrongful, as told on Tinder, and as told by Yahoo. His view is that Turing isn’t making a profit and he needs to find ways where it does. He has a duty to his shareholders. It seems incredibly short-term—one would hope that innovation is what turns around a pharmaceuticals’ business—and we come back to the notion that it all feels a bit lazy.

A version of this post originally appeared on my Tumblog.